Pembrolizumab showed a superior response in patients with the PD-L1 expression of at least 50% from tumor cells, and the median OS was 14.9 months at low doses and 17.3 months at high doses, compared with 8.2 months of docetaxel. This evidence concerns the gene CD274 and neoplasm.